Total Payments
$1.0M
2024 Payments
$89,682
Companies
26
Transactions
978
Medicare Patients
20,264
Medicare Billing
$1.7M
Payment Breakdown by Category
Consulting$489,514 (48.4%)
Other$331,537 (32.7%)
Research$140,418 (13.9%)
Travel$33,354 (3.3%)
Food & Beverage$17,281 (1.7%)
Gifts$250.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $489,514 | 269 | 48.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $306,937 | 132 | 30.3% |
| Unspecified | $140,418 | 8 | 13.9% |
| Travel and Lodging | $33,354 | 155 | 3.3% |
| Food and Beverage | $17,281 | 402 | 1.7% |
| Honoraria | $14,000 | 6 | 1.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $10,600 | 5 | 1.0% |
| Gift | $250.00 | 1 | 0.0% |
Payments by Type
General
$871,937
970 transactions
Research
$140,418
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $458,128 | 435 | $0 (2022) |
| ABBVIE INC. | $181,304 | 189 | $0 (2024) |
| Reichert, Inc. | $131,750 | 72 | $0 (2024) |
| NEW WORLD MEDICAL,INC. | $88,856 | 65 | $0 (2024) |
| Alcon Research LLC | $60,769 | 3 | $0 (2019) |
| Aerie Pharmaceuticals, Inc. | $27,721 | 32 | $0 (2021) |
| Glaukos Corporation | $21,971 | 45 | $0 (2024) |
| Nova Eye, Inc. | $18,205 | 11 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $14,324 | 24 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $2,529 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $89,682 | 96 | ABBVIE INC. ($70,650) |
| 2023 | $99,641 | 104 | ABBVIE INC. ($74,267) |
| 2022 | $130,594 | 118 | Allergan, Inc. ($39,024) |
| 2021 | $111,005 | 103 | Allergan, Inc. ($46,489) |
| 2020 | $146,063 | 133 | Allergan, Inc. ($93,640) |
| 2019 | $158,902 | 154 | Allergan Inc. ($88,478) |
| 2018 | $154,921 | 148 | Allergan Inc. ($82,588) |
| 2017 | $121,546 | 122 | Allergan Inc. ($107,909) |
All Payment Transactions
978 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Food and Beverage | In-kind items and services | $30.35 | General |
| Category: EYE CARE | ||||||
| 12/19/2024 | Glaukos Corporation | iDose (Device) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Glaucoma | ||||||
| 12/16/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: EYE CARE | ||||||
| 12/16/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | Alcon Vision LLC | HYDRUS Microstent (Device) | Food and Beverage | In-kind items and services | $122.83 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Ophthalmology | ||||||
| 11/15/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: EYE CARE | ||||||
| 11/13/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: Ophthalmology | ||||||
| 11/11/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $24.83 | General |
| 11/06/2024 | Glaukos Corporation | iDose (Device) | Food and Beverage | Cash or cash equivalent | $283.81 | General |
| Category: Glaucoma | ||||||
| 11/06/2024 | Glaukos Corporation | iDose (Device) | Food and Beverage | Cash or cash equivalent | $27.62 | General |
| Category: Glaucoma | ||||||
| 10/31/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Food and Beverage | In-kind items and services | $25.60 | General |
| Category: EYE CARE | ||||||
| 10/25/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: EYE CARE | ||||||
| 10/25/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Ophthalmology | ||||||
| 10/21/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $24.83 | General |
| 10/10/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Food and Beverage | In-kind items and services | $144.59 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Travel and Lodging | In-kind items and services | $74.17 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Travel and Lodging | In-kind items and services | $30.82 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Travel and Lodging | In-kind items and services | $15.00 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Travel and Lodging | In-kind items and services | $5.00 | General |
| Category: EYE CARE | ||||||
| 10/09/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Travel and Lodging | In-kind items and services | $597.95 | General |
| Category: EYE CARE | ||||||
| 10/09/2024 | ABBVIE INC. | XEN GLAUCOMA TREATMENT SYSTEM (Device) | Food and Beverage | In-kind items and services | $45.50 | General |
| Category: EYE CARE | ||||||
| 10/02/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $2.01 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Retrospective study evaluating Cypass surgical outcomes at a single subspecialty glaucoma practice, post-FDA approval | Alcon Research LLC | $30,375 | 1 |
| Retrospective study evaluating Cypass surgical outcomes at a single subspecialty glaucoma practice, post-FDA approval | Alcon Research Ltd | $30,375 | 1 |
| Research proposal for a retrospective study evaluating XEN45 surgical outcomes at a single subspeciality glaucoma practice post FDA approval | Allergan Inc. | $22,720 | 1 |
| Clearpath retrospective IIT | NEW WORLD MEDICAL,INC. | $22,000 | 2 |
| Research proposal for a retrospective study evaluating the surgical outcomes using a novel ab interno approach with the XEN45 gel stent and a Posterior Sweep of Tenon's Technique (PoST technique). | AbbVie Inc. | $8,375 | 1 |
| XEN-45 GEL STENT VERSUS TRABECULECTOMY IN GLAUCOMA: GOLD-STANDARD PATHWAY STUDY (GPS) | Allergan, Inc. | $10.13 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 5,374 | 5,917 | $2.1M | $454,569 |
| 2022 | 26 | 4,917 | 5,456 | $1.9M | $402,905 |
| 2021 | 26 | 5,456 | 6,025 | $2.0M | $435,302 |
| 2020 | 26 | 4,517 | 5,118 | $1.7M | $373,913 |
Total Patients
20,264
Total Services
22,516
Medicare Billing
$1.7M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 666 | 905 | $140,275 | $53,691 | 38.3% |
| 65820 | Incision to improve eye fluid flow | Facility | 2023 | 51 | 72 | $151,200 | $47,633 | 31.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 508 | 543 | $119,460 | $45,710 | 38.3% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 82 | 116 | $301,769 | $39,444 | 13.1% |
| 0449T | Insertion of initial aqueous fluid drainage device into eye | Facility | 2023 | 45 | 52 | $169,000 | $33,922 | 20.1% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2023 | 55 | 66 | $194,700 | $33,849 | 17.4% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 77 | 109 | $128,075 | $26,992 | 21.1% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 526 | 541 | $83,855 | $22,998 | 27.4% |
| 66180 | Creation of shunt to improve eye fluid flow using tissue graft | Facility | 2023 | 24 | 24 | $98,400 | $19,810 | 20.1% |
| 65855 | Laser repair to improve eye fluid flow | Office | 2023 | 54 | 82 | $104,550 | $15,872 | 15.2% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 810 | 849 | $76,410 | $15,616 | 20.4% |
| 92250 | Photography of the retina | Office | 2023 | 593 | 593 | $103,775 | $14,919 | 14.4% |
| 92133 | Imaging of optic nerve | Office | 2023 | 585 | 595 | $154,700 | $14,261 | 9.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 132 | 135 | $27,580 | $13,030 | 47.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 102 | 102 | $31,620 | $11,702 | 37.0% |
| 66250 | Revision or repair of operative wound of eye | Office | 2023 | 15 | 21 | $45,100 | $10,852 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 128 | 133 | $20,180 | $9,058 | 44.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 51 | 51 | $13,770 | $5,597 | 40.6% |
| 66761 | Creation of eye fluid drainage tracts in iris using a laser, per session | Office | 2023 | 11 | 21 | $26,250 | $4,895 | 18.6% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 123 | 152 | $66,500 | $4,347 | 6.5% |
| 92145 | Measurement of corneal pressure | Office | 2023 | 488 | 495 | $24,750 | $4,012 | 16.2% |
| 66710 | Destruction of lens tissue using laser | Facility | 2023 | 11 | 12 | $19,500 | $2,961 | 15.2% |
| 92134 | Imaging of retina | Office | 2023 | 46 | 50 | $13,000 | $1,410 | 10.8% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2023 | 155 | 155 | $8,525 | $1,149 | 13.5% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Facility | 2023 | 19 | 20 | $6,300 | $502.51 | 8.0% |
About Davinder Grover, M.D, MPH
Davinder Grover, M.D, MPH is a Ophthalmology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1194861674.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Davinder Grover, M.D, MPH has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $89,682 received in 2024. These payments were reported across 978 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($489,514).
As a Medicare-enrolled provider, Grover has provided services to 20,264 Medicare beneficiaries, totaling 22,516 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Dallas, TX
- Active Since 01/30/2007
- Last Updated 10/01/2011
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1194861674
Products in Payments
- XEN (Device) $188,647
- XEN GLAUCOMA TREATMENT SYSTEM (Device) $183,984
- DURYSTA (Drug) $102,779
- Ahmed Glaucoma Valve (Device) $64,580
- CyPass (Device) $61,030
- Clearpath (Device) $22,000
- VYZULTA (Drug) $14,410
- rhopressa (Drug) $11,261
- rocklatan (Drug) $9,172
- Rhopressa (Drug) $7,266
- iDose (Device) $5,637
- iStent inject Trabecular Micro-Bypass Stent System (Device) $5,198
- iStent Trabecular Micro-Bypass Stent System (Device) $4,987
- LUMIGAN (Drug) $4,690
- TONO-VERA TONOMETER US STARTER KIT HUMAN RECHARGABLE (Device) $4,500
- RESTASIS (Drug) $4,020
- iStent inject W (Device) $2,500
- Kahook Dual Blade (Device) $2,276
- XIIDRA (Drug) $2,234
- ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM (Device) $1,995
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Dallas
Dr. Oluwatosin Smith, M.d, M.D
Ophthalmology — Payments: $1.5M
Ophthalmology $1.5M
Dr. Ashkan Abbey, M.d, M.D
Ophthalmology — Payments: $624,167
Ophthalmology $624,167
Dr. Karl Csaky, Md, MD
Ophthalmology — Payments: $583,703
Ophthalmology $583,703
Jeffrey Whitman, M.d, M.D
Ophthalmology — Payments: $272,915
Ophthalmology $272,915
Robert Wang, M.d, M.D
Ophthalmology — Payments: $187,984
Ophthalmology $187,984
Arvind Neelakantan, Md, MD
Ophthalmology — Payments: $112,729
Ophthalmology $112,729